Skip to content

Clinical trials

Observational Thyroid Diseases trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Thyroid Diseases Phase: Observational Country / region: China Clear all

15 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20171
20191
20212
20231
20245
20254
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting7
Unknown status4
Active, not recruiting1
Completed1
Enrolling by invitation1
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Shanghai 6th People's Hospital3
Beijing Friendship Hospital1
Fujian Medical University1
Guang'anmen Hospital of China Academy of Chinese Medical Sciences1
Peking University Shenzhen Hospital1
Second Affiliated Hospital of Nanchang University1
Second Affiliated Hospital of Xi'an Jiaotong University1
Second Affiliated Hospital, Zhejiang University, School of Medicine1
Shanghai Changzheng Hospital1
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Thyroid Diseases15
Thyroid Neoplasms4
Cardiovascular Diseases2
Thyroid Nodule2
Amyloidosis1
Arthritis, Rheumatoid1
Bone Diseases, Metabolic1
Diabetes Mellitus1
Digestive System Diseases1
Dyslipidemias1

Trials

Showing 1 to 15 of 15. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.